The purpose of this study is to understand how dipeptidyl peptidase IV (DPP4) inhibition in
diabetics affects hemodynamic parameters and sympathetic activation in the setting of
increasing concentrations of neuropeptide Y, an endogenous peptide. The central hypothesis is
that DPP4 inhibition decreases degradation of neuropeptide Y, resulting in increased
vasoconstriction and sympathetic activation.